FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.4-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

773881003: Antiparkinson therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3726863016 Antiparkinson therapeutic role en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3726864010 Antiparkinson therapeutic role (role) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3726863016 Antiparkinson therapeutic role en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3726864010 Antiparkinson therapeutic role (role) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antiparkinson therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier (core metadata concept)
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release orodispersible tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Selegiline only product in oromucosal dose form Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Carbidopa- and levodopa-containing product in oromucosal dose form Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing only carbidopa and levodopa in oromucosal dose form (medicinal product form) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing istradefylline (medicinal product) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing only istradefylline (medicinal product) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing istradefylline in oral dose form (medicinal product form) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing only istradefylline in oral dose form (medicinal product form) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Opicapone 50 mg oral capsule Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Opicapone 25 mg oral capsule Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Carbidopa 25 mg and levodopa 100 mg prolonged-release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely carbidopa 50 milligram and levodopa 200 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely bromocriptine (as bromocriptine mesilate) 800 microgram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Carbidopa anhydrous (as carbidopa) 25 mg oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Carbidopa anhydrous (as carbidopa) 12.5 mg and levodopa 50 mg oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely rasagiline (as rasagiline tartrate) 1 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Rasagiline (as rasagiline mesilate) 1 mg oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely rasagiline (as rasagiline mesilate) 500 microgram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Biperiden hydrochloride 4 mg prolonged-release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 3.15 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.05 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 2.1 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Pramipexole (as pramipexole dihydrochloride) 520 microgram prolonged-release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 260 microgram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Piribedil-containing product in oral dose form Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely piribedil 50 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Piribedil-containing product Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Piribedil only product Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing only piribedil in oral dose form (medicinal product form) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 88 microgram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Pramipexole (as pramipexole dihydrochloride) 350 microgram oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Pramipexole (as pramipexole dihydrochloride) 700 microgram oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 520 microgram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.57 milligram/1 each prolonged-release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Pramipexole (as pramipexole dihydrochloride) 2.62 mg prolonged-release oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely pramipexole (as pramipexole dihydrochloride) 1.05 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely biperiden lactate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely ropinirole (as ropinirole hydrochloride) 4 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely ropinirole (as ropinirole hydrochloride) 3 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Ropinirole (as ropinirole hydrochloride) 500 microgram oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Rotigotine 125 microgram/hour prolonged-release transdermal patch Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Rotigotine 41.667 microgram/hour prolonged-release transdermal patch Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Carbidopa anhydrous (as carbidopa) 43.75 mg and entacapone 200 mg and levodopa 175 mg oral tablet Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)
Product containing precisely carbidopa anhydrous (as carbidopa) 12.5 milligram and entacapone 200 milligram and levodopa 50 milligram/1 each conventional release oral tablet (clinical drug) Plays role False Antiparkinson therapeutic role Inferred relationship Existential restriction modifier (core metadata concept)

Start Previous Page 3 of 3

This concept is not in any reference sets

Back to Start